Stock 2181 MABPHARM LIMITED
Add to a list

Mabpharm Limited Share Price

Stocks

2181

KYG5780F1046

Biotechnology & Medical Research

Market Closed - Hong Kong S.E.
Other stock markets
 09:08:11 17/07/2026 BST 		5-day change 1st Jan Change
0.4050 HKD -6.90% Intraday chart for Mabpharm Limited +2.53% -19.00%
06-24 Mabpharm Limited Receives Approval for New Drug Application of CMAB807X (Denosumab Injection) CI
06-09 Mabpharm Limited Receives Approval For New Drug Application Of CMAB807 Denosumab Injection From National Medical Products Administration CI

Valuation: Mabpharm Limited

Market Cap 1.44B 1.67B 213M 187M 172M 159M 299M 20.54B 306M 2.06B 810M 10.08B 801M 784M 34.64B P/E 2024
-8.48x
P/E 2025 44.9x
Enterprise Value 1.66B 1.92B 246M 215M 198M 183M 344M 23.63B 352M 2.37B 932M 11.59B 922M 902M 39.86B EV / Sales 2024
5.06x
EV / Sales 2025 3.2x
Free-Float
22.82%
Yield 2024 *
-
Yield 2025 -
* Estimated data More valuation ratios

Chart: Mabpharm Limited

Dynamic Chart

Latest news : Mabpharm Limited

06-24 Mabpharm Limited Receives Approval for New Drug Application of CMAB807X (Denosumab Injection) CI
06-09 Mabpharm Limited Receives Approval For New Drug Application Of CMAB807 Denosumab Injection From National Medical Products Administration CI
06-09 Mabpharm's Application for Osteoporosis Drug Approved in China MT
03-26 Mabpharm Limited Reports Earnings Results for the Full Year Ended December 31, 2025 CI
03-26 Mabpharm FY profit and total comprehensive income attributable rmb57.1 million RE
12-05 Mabpharm Limited Announces Change of Address of Principal Place of Business in Hong Kong CI
31/10/25 Mabpharm Limited Announces Board and Committee Changes, Effective October 31, 2025 CI
28/08/25 Mabpharm Limited Reports Earnings Results for the Half Year Ended June 30, 2025 CI
27/03/25 Mabpharm Shrinks Loss by 39% in 2024 MT
26/03/25 Mabpharm Limited Reports Earnings Results for the Full Year Ended December 31, 2024 CI
03/01/25 Mabpharm's Infliximab Drug Receives Approval from Pakistan's Drug Regulator MT
02/01/25 Mabpharm Limited Announces Approval from the Drug Regulatory Authority of Pakistan on the Registration of Core Product, CMAB008 (Infliximab for Injection) CI
27/12/24 Mabpharm Limited Announces Approval from the Indonesian National Agency of Drug and Food Control on the Marketing Authorization of its Core Product, CMAB008 (Infliximab for Injection) CI
More news

Press Releases: Mabpharm Limited

13/11/23 Cryopyrin-Associated Periodic Syndrome Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated) AQ
20/07/21 Mabpharm : Sorrento Announces Its Partner Mabpharm Has Received Marketing Approval In China For Infliximab Biobetter AQ
30/04/21 Mabpharm : POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON FRIDAY, APRIL 30, 2021 PU
21/04/21 Mabpharm : FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, JUNE 18, 2021 PU
12/04/21 Mabpharm : (1) DISCLOSEABLE AND CONNECTED TRANSACTION IN RELATION TO THE ACQUISITION OF CMAB807 (2) CONTINUING CONNECTED TRANSACTIONS IN RELATION TO THE CLINICAL TRIALS AGREEMENT AND THE CDMO AGREEMENT AND (3) NOTICE OF EXTRAORDINARY GENERAL MEETING PU
More press releases

Quotes and Performance

1 day-6.90%
1 week+2.53%
Current month-3.57%
1 month+5.19%
3 months-7.95%
6 months-20.59%
Current year-19.00%
More quotes

Course Extremes

1 week 0.4
Extreme 0.395
 0.44
1 month 0.32
Extreme 0.32
 0.45
Current year 0.31
Extreme 0.31
 0.81
1 year 0.31
Extreme 0.31
 0.88
3 years 0.25
Extreme 0.25
 0.94
5 years 0.25
Extreme 0.25
 1.34
10 years 0.25
Extreme 0.25
 1.8
More quotes

Managers and Directors: Mabpharm Limited

Manager TitleAgeSince
Hao Wang CEO
 Chief Executive Officer 57 27/10/2020
Sheng Hou PRN
 Corporate Officer/Principal 49 30/11/2023
Jing Tao PRN
 Corporate Officer/Principal 53 02/08/2018
Director TitleAgeSince
Shu Ge Jiao CHM
 Chairman 60 19/07/2018
Ho Ming Leung BRD
 Director/Board Member 42 16/06/2022
Wei Zhu Qian BRD
 Director/Board Member 50 03/02/2015
More insiders

Latest insider transactions

Date Insider Type Main position Quantity % Market Cap.
10/02/23
Jing Tao
Other

Director

75,192 0.0018%
Transaction History

Bio Therapeutic Drugs

Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Change 5-day change 1-year change 3-year change Capi.($)
MABPHARM LIMITED Stock Mabpharm Limited
-6.90%+2.53%-19.00%-46.00% 229M
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-7.17%-2.63%+49.59%+74.24% 55.98B
ARGENX SE Stock argenx SE
+0.24%-5.62%+54.73%+125.15% 53.69B
INSMED INCORPORATED Stock Insmed Incorporated
+0.80%-8.41%+3.57%+425.83% 23.29B
BIONTECH SE Stock BioNTech SE
-0.09%-1.61%-18.68%-15.48% 23.15B
WUXI BIOLOGICS (CAYMAN) INC. Stock WuXi Biologics (Cayman) Inc.
-5.95%-0.22%+35.96%-9.58% 20.58B
GENMAB A/S Stock Genmab A/S
-1.14%-3.16%+32.88%-28.80% 17.76B
PHARMAESSENTIA CORPORATION Stock PharmaEssentia Corporation
-5.16%-7.00%+177.56%+326.39% 16.09B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. Stock Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
-6.91%+2.40%+36.86%+636.97% 15.93B
EXELIXIS, INC. Stock Exelixis, Inc.
+0.43%-2.07%+24.79%+188.40% 14B
Average -3.18%-0.12%+37.83%+167.71% 24.07B
Weighted average by Cap. -2.92%-2.19%+43.52%+156.84%
See all sector performances

Financials

2024 2025
Net sales 258M 299M 38.16M 33.42M 30.85M 28.41M 53.39M 3.67B 54.66M 369M 145M 1.8B 143M 140M 6.19B 646M 748M 95.47M 83.61M 77.18M 71.09M 134M 9.19B 137M 923M 362M 4.51B 359M 351M 15.5B
Net income -128M -148M -18.91M -16.56M -15.28M -14.08M -26.45M -1.82B -27.09M -183M -71.77M -893M -71M -69.43M -3.07B 57.13M 66.18M 8.44M 7.39M 6.82M 6.29M 11.81M 813M 12.09M 81.59M 32.05M 399M 31.7M 31M 1.37B
Net Debt 222M 257M 32.84M 28.76M 26.55M 24.45M 45.95M 3.16B 47.05M 317M 125M 1.55B 123M 121M 5.33B 217M 252M 32.14M 28.14M 25.98M 23.93M 44.96M 3.09B 46.04M 311M 122M 1.52B 121M 118M 5.22B
* Estimated data More financial data

Company Profile

Logo Mabpharm Limited
Mabpharm Ltd is an investment holding company primarily engaged in the research, development and production of monoclonal antibody drugs for cancers and autoimmune diseases. The Company’s main products include CMAB009 Enlituo (cetuximab β injection), CMAB007 Aomaishu (Omalizumab α for Injection), CMAB008 Leiting (infliximab for injection) and other products. The Company’s products are mainly used for colorectal cancer, asthma, urticaria, rheumatoid arthritis, ulcerative colitis in adults and other diseases. The Company is also engaged in the transfer of intellectual property. The Company mainly conducts its business in the domestic market.
Employees
389
Sector
Biotechnology & Medical Research
More about the company

Quotes

Date Price Change Volume
17/07/26 HK$0.4050 -6.90% 0
16/07/26 HK$0.4350 +10.13% 4,000
15/07/26 HK$0.3950 0.00% 0
14/07/26 HK$0.3950 -8.14% 74,000
13/07/26 HK$0.4300 0.00% 0

Delayed Quote Hong Kong S.E.

More quotes

Income Statement and Estimates

More financial data
  1. Stock Market
  2. Stocks
  3. 2181 Stock

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

MarketScreener
United-States
MarketScreener Canada
Canada

MIDDLE EAST

MarketScreener Saudi Arabia
Saudi Arabia
MarketScreener UAE Emirates
United Arab Emirates

EUROPE

Zonebourse
France
MarketScreener Deutschland
Deutschland
Zonebourse Suisse
Suisse
MarketScreener Schweiz
Schweiz
MarketScreener Italia
Italia
MarketScreener Österreich
Österreich
MarketScreener België
België
MarketScreener Nederland
Nederland
MarketScreener España
España
MarketScreener Sverige
Sverige
MarketScreener UK
United Kingdom

APAC

MarketScreener Australia
Australia
MarketScreener India
India
MarketScreener Hong Kong
Hong Kong